ClinicalTrials.gg

Program

XT-150

A development code.

Its studies are mostly in Osteoarthritis, Knee · Amyotrophic Lateral Sclerosis · Back Pain · Neuralgia · Osteoarthritis, led by Xalud Therapeutics.

Furthest: phase 2, since Oct 9, 20198 company-led studies, 1 open or runningNext primary completion: Jun 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Xalud Therapeutics81 open or runningphase 2since Oct 9, 2019Sep 11, 2017Jun 2028phase 1 · NCT06704347

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 11, 2017First study: phase 1 study in Osteoarthritis, KneeFirst studyNCT03282149 · 24 enrolled · Australia
  2. Mar 13, 2018Phase 1 study in Osteoarthritis, KneeNCT03477487 · 32 enrolled · United States
  3. Dec 6, 2018Phase 1 study in Osteoarthritis, KneeNCT03769662 · 16 enrolled · Australia
  4. Oct 9, 2019Phase 2 study in Osteoarthritis, KneeNCT04124042 · 289 enrolled · United States, Australia
  5. Jun 24, 2020Phase 1 study in NeuralgiaNCT04466410 · 5 enrolled · Australia
  6. Apr 7, 2021Phase 2 study in Osteoarthritis, SpineNCT04841512 · Australia
  7. Dec 13, 2021Phase 2 study in Back PainNCT05196919 · 75 enrolled · United States
  8. Nov 20, 2024Phase 1 study in Amyotrophic Lateral SclerosisNCT06704347 · 8 planned · United States

Ahead

  1. Jun 2028Primary completion: phase 1 study in Amyotrophic Lateral SclerosisNCT06704347

TargetBeta

IL10 →read by rule
“XT-150 is a small piece of plasmid DNA (genetic material) that produces a variant of the anti-inflammatory cytokine, Interleukin 10 (IL-10).”study text, by rule · the study

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06704347Amyotrophic Lateral Sclerosis · United States1Not yet recruitingJun 20288
NCT05196919Back Pain · United States2CompletedSep 20, 202375
NCT04841512Osteoarthritis, Spine · Australia2WithdrawnMar 1, 20220
NCT04466410Neuralgia · Australia1TerminatedSep 27, 20225
NCT04124042Osteoarthritis, Knee · United States, Australia2CompletedApr 26, 2022289
NCT03769662Osteoarthritis, Knee · Australia1CompletedOct 30, 201916
NCT03477487Osteoarthritis, Knee · United States1CompletedJul 19, 201932
NCT03282149Osteoarthritis, Knee · Australia1CompletedMar 31, 201924

How it is read

Names in the registry

  • “XT-150”, 8 entries

Codes read as this program: XT150.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.